New Feature: A New Era for News on Finviz

BeyondSpring, Inc.

Contributing Author

Recent Articles by BeyondSpring, Inc.

Feb-09	BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360 Conference BYSI GlobeNewswire
Dec-12	BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path BYSI GlobeNewswire
Dec-11	BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025 BYSI +7.92% GlobeNewswire
Nov-12	BeyondSpring Reports Third-Quarter 2025 Financial Results and Provides Corporate Update BYSI GlobeNewswire
Aug-13	BeyondSpring Reports Second-Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment BYSI GlobeNewswire
Jul-07	BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure BYSI GlobeNewswire
Jun-03	BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting BYSI GlobeNewswire
May-28	BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting BYSI -5.68% GlobeNewswire
May-12	BeyondSpring Reports First-Quarter 2025 Financial Results and Provides Corporate Update BYSI GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.